Shares of TG Therapeutics Inc (NASDAQ:TGTX) are climbing Wednesday afternoon following the release of early-stage clinical trial data for a new formulation of its multiple sclerosis drug, BRIUMVI. Here’s what investors need to know.
- TG Therapeutics stock is surging to new heights today. Why are TGTX shares rallying?
New At-Home Injection Method Shows Promise
The biotech company announced data from its Phase 1 trial evaluating a high-concentration subcutaneous formulation of the treatment compared to its approved intravenous version. The trial demonstrated a mean bioavailability of greater than 60% relative to IV administration.
Additionally, the treatment resulted in B-cell depletion consistent with the IV version, with no new safety signals observed. Local injection-site reactions occurred in less than 5% of patients.
Management stated that the pharmacokinetic modeling supports a quarterly subcutaneous dosing regimen. This regimen is currently being evaluated in a fully enrolled Phase 3 trial.
Topline data from the Phase 3 study is expected in late 2026 or early 2027, with a potential regulatory approval goal targeted for 2028. If approved, the self-administered formulation could expand the addressable market for the franchise.
TGTX Technical Levels To Watch
From a longer-term trend view, TGTX is still in a constructive uptrend: it’s trading 1.7% above the 20-day SMA ($39.95) and 24.7% above the 200-day SMA ($32.59), with a bullish 20-day-over-50-day setup and a golden cross (50-day above 200-day) that formed in April. The stock is also pressing toward the top of its 52-week range ($25.28 low to $44.65 high), which can attract momentum buyers but also brings overhead supply into view.
For momentum, MACD is the cleaner lens right now: it’s below its signal line with a negative histogram, which suggests upside pressure is cooling versus the prior upswing unless buyers can re-accelerate the trend. In plain terms, MACD below the signal line often means the rally is losing steam even if price is still holding above key moving averages.
- Key Resistance: $44.50 — sits just below the $44.65 52-week high zone, where breakouts often need extra volume to clear
- Key Support: $33.00 — lines up near the 200-day area ($32.59) and a prior demand zone where buyers have shown up
How TGTX Is Outperforming Healthcare Sector
TGTX is outperforming the Healthcare sector by about 10.39 percentage points today, which is a strong “stock-specific” tell given XLV is up 1.05% rather than ripping higher across the board. When a single name leads that hard inside a green sector, traders usually treat the news flow as the main driver rather than sector beta.
Zooming out, Healthcare has gained 2.26% over the past 30 days but is down 3.84% over the past 90 days, so the group has been more choppy than trending. That backdrop makes clean, catalyst-backed strength more important—because leadership can rotate quickly if the sector slips back into its weaker intermediate-term tape.
TGTX Stock Price Movement Today
TGTX Stock Price Activity: TG Therapeutics shares were up 9.88% at $40.26 at the time of publication on Wednesday, according to Benzinga Pro data.
Image: Adobe Stock Images
Recent Comments